Richard Carter Head of Industry Sponsorship Department of Health London

1
Richard CarterHead of Industry Sponsorship
Department of HealthLondon
2
Presentation

• Co-operation of public authorities and industry
  why is it necessary to work together?
• The UK experience

3
Outline of the presentation

• The DH role in co-ordinating policy
• Our aim and why we do this
• How we go about it
• - Pharmaceuticals
• - Medical technology
• Characteristics of the relationship

4
Department of Health Role

• Sets strategic direction for delivery of health
  and social care services
• Sponsoring UK Government Department for the
  pharmaceutical and medical technology industries
• DH has the lead role in co-ordinating policy for
  both pharmaceutical and medical technology
  industries

5
Our aim

• The Government's strategy is to build on the UKs
  reputation as being a leader in life sciences,
  and to work with both industries to improve the
  environment for them to continue to innovate.

6

Why do we do this?

• Importance of these industries to the economy of
  the UK
• Vital role of each sector in supporting
  Governments health goals and policies
• Importance of innovation to health care reform

7
Pharmaceutical Medical Technology sectors in
the UK

• Pharmaceutical Industry
• Invests over 3bn annually in RD in the UK
• 12bn of medicines exported from the UK annually
• 68,000 directly employed by the pharmaceutical
  industry
• 16 of the worlds top-selling 75 medicines
  discovered in the UK

• Medical technology
• Annual output is in the region of 4bn including
  2.2bn to the NHS
• Exports are about 2bn
• 55,000 directly employed by the medical
  technology industry

8
How do we go about it? Pharmaceuticals

• History of the relationship is long
• Since 1999 more systematic architecture of
  engagement
• 1999-2001 PICTF
• 2001-present MISG
• MISG - industry side membership global,
  government side ministers and top officials
• Meets twice a year
• Joint consideration of strategic issues of common
  interest, e.g. science education

9
Close Dialogue Partnership with Industry-MISG
Long Term Leadership Strategy

• Ministerial Industry Strategy Group (MISG)
• MISG has overseen the development of the Long
  Term Leadership Strategy for Medicines (LTLS)
  which is designed to
• secure the provision of safe and effective
  medicines for patients
• maintain and strengthen the UK pharmaceutical
  industry within Europe
• and to advance healthcare innovation in the UK.

10
Close Dialogue Partnership with Industry- MISG
- Long Term Leadership Strategy

• Three workstreams have reported on their
  conclusions
• Partnership Working Group Dealing with the
  industrys relationships with the NHS in England
  and with uptake of cost effective medicines
• European Working Group Improving the business
  and technology environment for the pharmaceutical
  industry in Europe
• Regulatory Working Group Developing the
  regulatory environment in the UK and Europe so as
  better to serve needs of all stakeholders

11
Pharmaceuticals - LTLS Report February 2007
12
How do we go about it Medical Technology

• Shorter history of joint engagement
• Healthcare Industries Task Force (HITF) a year
  long joint Initiative was set up in 2003
• Beginning of an important dialogue between
  Government and the sector
• Implementation of its key outputs from 2004
• New strategic group Ministerial Medical
  Technology Strategy Group set up to take
  forward recommendations
• Will meet twice a year
• Will consider strategic issues of common
  interest, e.g. small business support in this
  sector, innovation

13
Key outputs of HITF

• Integration of technology evaluation into
  procurement - Centre for Evidence-based
  Purchasing (CEP)
• Establishment of a National Innovation Centre
  (NIC)
• Strengthened RD environment for medical
  technologies
• Streamlined procurement process
• Continuing shared strategic agenda and
  architecture within which to pursue it

14
Medical Technology - Published Reports 2004 and
2007

• Further details are available on
  www.advisorybodies.doh.gov.uk/hitf

15
Characteristics of the relationships

• Well established long term engagement
• Very senior representation from both sides on the
  two joint government/industry groups
• Genuine interest on both sides in holding
  constructive dialogue at strategic level
• Openness and transparency
• Ability to disagree without rupturing the
  connection
• Strong horizontal working across relevant
  government departments

16
The UK Government pharmaceutical medical
technology Industry linkages a schematic overview

• Pharmaceuticals

FCO/UKTI Inward investment

• Medical Technology

DIUS Skills
DFID Access to medicines
NHSIII/NIC
HO Animal rights legislation
DBERR Science base
DH Co-ordination policy/ Purchaser/NHS
NHS PASA Procurement, device evaluation
HMT Tax incentives/ Science strategy
MHRA EU medicines/device legislation
NICE Appraisals of New technologies
UKCRC Translational Clinical research
OSCHR Health research
17
Key Messages

• Government committed to a strong relationship
  with industry
• Both parties to the relationship benefit
• Working in partnership wherever possible has
  enabled us to achieve many shared goals